Last reviewed · How we verify

NCT03702088

Place of the Hevylite Test in the Evaluation of MRD in Myeloma

Status unknown Last updated 19 November 2019
What this trial tests

trial in Myeloma in 124 participants. Status unknown.

Timeline
1 October 2018
Primary endpoint
1 December 2020
30 December 2020

Quick facts

Lead sponsorUniversity Hospital, Montpellier
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment124
Start date1 October 2018
Primary completion1 December 2020
Estimated completion30 December 2020
Sites1 location across France

Conditions studied

Sponsor

University Hospital, Montpellier

Who can join

18 and older, any sex, with Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study aiming at testing the positive predictive value of the Hevylite blood test in detecting minimal residual disease in myeloma compared to an invasive method requiring bone marrow sample by multi-parametric flow cytometry

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Myeloma

Currently open trials in the same condition.

Other University Hospital, Montpellier trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03702088.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing